Companion and Complementary Diagnostics: From Biomarker Discovery to Clinical Implementation provides readers with in-depth insights into the individual steps in the development of companion diagnostic assays, from the early biomarker discovery phase straight through to final regulatory approval. Further, the clinical implementation of companion diagnostic testing in the clinic is also discussed. As the development of predictive or selective biomarker assays linked to specific drugs is substantially increasing, this book offers comprehensive information on this quickly-evolving area of biomedicine. It is an essential resource for those in academic institutions, hospitals and pharma, and biotech and diagnostic commercial companies.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
1. Foreword 2. An Introduction to Companion and Complementary Diagnostics 3. The Drug-Diagnostic Co-Development Model 4. Systems Biology and Biomarker Development in Cancer Signaling Therapy 5. Immunohistochemistry 6. In Situ Hybridization 7. Polymerase Chain Reaction 8. Next Gen Sequencing Based Companion Diagnostics: From Biomarker Discovery to Clinical Implementation 9. Current Next Generation Sequencing Based Companion Diagnostics and their Analytical Validation 10. Companion and Complementary Diagnostics by Mass Spectrometry 11. Molecular Imaging Companion Diagnostics 12. Circulating Tumor DNA Analysis and Opportunities for Personalized Cancer Medicine 13. Companion Diagnostics Assay DevelopmentPrototype, Verification and Analytical Validation 14. Tissue is the Issue: Challenges in Oncology Clinical Trial Tissue Sample Collection for Biomarker Analyses and Companion Diagnostics 15. Adaptive Trial Designs for Biomarker Driven Clinical Trials with Quantitative and Multiple Candidate Biomarkers 16. Companion Diagnostics Based on Time to Event Data 17. Regulatory Requirements for Companion Diagnostics and Drug-Diagnostic Co-Development in the United States of America 18. Companion Diagnostics and Biomarker Tests in the European Medicines Agency's Assessment of Medicinal Products 19. Understanding the Current Regulatory Landscape for Companion Diagnostic Products in China 20. Regulatory requirements for companion diagnostics
Japan 21. Economic Evaluation of Companion and Complementary Diagnostics 22. A Risk Based Paradigm of Biomarkers in Clinical Trials 23. Implementing Companion Diagnostic Testing in the Clinic 24. Osimertinib (TAGRISSO) and the cobas EGFR Mutation Test v2 25. QMS Omecamtiv Mecarbil Immunoassay and Omecamtiv Mecarbil Co-Development 26. Current Status and Future Direction of Companion Diagnostics
